RxDoctor Payments Data

Robert Drvol, MD

Adolescent Medicine · Omaha, NENPI 1508916594

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 91.4% of the total across 12 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Inspire Medical Systems, Inc. at 24.2% of the total.

$227in general payments, 2019–2025

Across 12 payments — averaging $18.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Inspire Medical Systems, Inc.$55
  • Abbott$49
  • Inari Medical, Inc.$32
  • Novo Nordisk$22
  • Biogen$20
  • Novartis$14
  • plus $37 from 3 others

What the payments were for

  • Food & beverage$20891%
  • Education$209%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

Too few adolescent medicine providers in Nebraskato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$154,892
Medicare patients
435
Services billed
4,065

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide140$161,112
EliquisApixaban196$142,710
OzempicSemaglutide92$91,614
JanuviaSitagliptin Phosphate42$52,775
JardianceEmpagliflozin55$48,646
TrulicityDulaglutide42$41,987
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog19$30,647
XareltoRivaroxaban27$25,370
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$23,493
FarxigaDapagliflozin Propanediol14$16,761
MyrbetriqMirabegron30$15,586
LinzessLinaclotide13$12,382
SymbicortBudesonide/Formoterol Fumarate28$10,866
Lantus SolostarInsulin Glargine,hum.Rec.Anlog70$9,673
Gabapentin339$7,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$22$91,61492 claims
Boehringer IngelheimJardiance$13$48,64655 claims
GSKTrelegy Ellipta, Breo Ellipta$11$29,35942 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few adolescent medicine providers in Nebraskaon file to place this against a meaningful peer group, so we don't.

Other adolescent medicine in Omaha

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →